[(13S,15R)-2-fluoro-13-methyl-15-[3-[(5-methyl-1,3-thiazol-2-yl)amino]-3-oxopropyl]-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] trifluoromethanesulfonate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: [(13S,15R)-2-fluoro-13-methyl-15-[3-[(5-methyl-1,3-thiazol-2-yl)amino]-3-oxopropyl]-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] trifluoromethanesulfonate
• 化学式: C₂₆H₂₈F₄N₂O₅S₂
• 分子量: 588.6
• InChiKey: YIZOQVFKLMRJIK-VZRRMLPQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  39
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  139
• 氢给体数：
  1
• 氢受体数：
  11

文献信息

• Therapeutically active estratrienthiazole derivatives as inhibitors of 17 B-hydroxysteroid dehydrogenase, type 1
  申请人：FORENDO PHARMA LTD

  公开号：US10377791B2

  公开（公告）日：2019-08-13

  The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R6 are as defined in the claims. The invention further relates to their use as inhibitors of 17β-HSD and in treatment or prevention of steroid hormone de-pendent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17β-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.

  本发明涉及式（I）化合物及其药学上可接受的盐，其中 R1 至 R6 如权利要求中定义。本发明进一步涉及其作为 17β-HSD 抑制剂的用途，以及在治疗或预防类固醇激素依赖性疾病或紊乱中的用途，例如需要抑制 17β-HSD1 酶和/或需要降低内源性雌二醇浓度的类固醇激素依赖性疾病或紊乱。本发明还涉及上述化合物的制备，以及包含一种或多种上述化合物或其药学上可接受的盐作为活性成分的药物组合物。
• THERAPEUTICALLY ACTIVE ESTRATRIENTHIAZOLE DERIVATIVES AS INHIBITORS OF 17B-HYDROXYSTEROID DEHYDROGENASE, TYPE 1
  申请人：Forendo Pharma Ltd

  公开号：EP3013845B1

  公开（公告）日：2020-03-18
• THERAPEUTICALLY ACTIVE ESTRATRIENTHIAZOLE DERIVATIVES AS HINIBITORS OF 17 B-HYDROXYSTEROID DEHYDROGENASE, TYPE 1
  申请人：FORENDO PHARMA LTD

  公开号：US20170114090A1

  公开（公告）日：2017-04-27

  The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R6 are as defined in the claims. The invention further relates to their use as inhibitors of 17β-HSD and in treatment or prevention of steroid hormone de-pendent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17β-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.